DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy
Por:
Echepare, M, Picabea, B, Arricibita, A, Teijeira, A, Pasquier, A, Zandueta, C, Otegui, N, Santamaría, E, Fernández-Irigoyen, J, Romero, O, Sanchez-Cespedes, M, Lecanda, F, Hernández, J, Felip, E, Cruz-Bermúdez, A, Provencio, M, Gentili, M, Facchinetti, F, Roz, L, Montuenga, LM and Valencia, K
Publicada:
1 mar 2025
Ahead of Print:
1 mar 2025
Resumen:
Introduction: Chemotherapy continues to be the standard treatment for patients noneligible for targeted or immune- based therapies; nevertheless, treatment resistance remains a major clinical challenge. We previously found that expression levels of DSTYK, a poorly explored dual serine/ threonine and tyrosine kinase frequently amplified in cancer, identified patients with lung cancer exhibiting poor response to immune checkpoint inhibitors, and found that its inhibition sensitizes to immunotherapy. Seeking to explore the potential of DSTYK targeting in additional indications, we investigated the functional relevance and actionability of DSTYK in lung cancer chemoresistance. Methods: In silico analysis to study the differential sensitivity to paclitaxel, carboplatin, pemetrexed, and cisplatin drugs was performed using pan-cancer human cancer cell line DSTYK CN data downloaded from Depmap portal (https://depmap.org/portal/depmap/). Two cohorts of patients with lung cancer were used. An adjuvant cohort composed of patients with advanced IV-stage lung adenocarcinoma treated with carboplatin plus paclitaxel or carboplatin plus pemetrexed in the first line from VHIO; A neoadjuvant cohort including resectable stage IIIA or IIIB NSCLC tumor samples of patients from NADIM I and NADIM clinical trials perioperative treated with nivolumab plus chemotherapy (carboplatin & thorn; paclitaxel). DSTYK CN was assessed by fluorescence in situ hybridization and quantitative reverse transcription-polymerase chain reaction. Proteomics and bioinformatic analyses were performed to study differentially expressed protein signatures. Functional in vitro experiments (adhesion, migration, and invasion) in both murine and human systems, and in vivo lung orthotopic, intracardiac, and intratibial xenograft and syngeneic models complete the study. Results: We show that DSTYK depletion specifically sensitizes lung cancer cells to taxane-based chemotherapy, particularly in combination with carboplatin. Mechanistically, DSTYK ablation remodels the cytoskeleton and impairs distant invasion and metastatic outgrowth in vivo. DSTYK downregulation sensitizes both primary and metastatic lung tumors to chemoimmunotherapy treatment leading to tumor regression in mouse models. Consistently, clinical data of patients with early and advanced lung cancer-in the neoadjuvant and adjuvant settings-show a strong correlation between DSTYK amplification and taxane resistance, underscoring the clinical significance of our findings to inform treatment decision-making. Conclusions: Collectively, our data indicates that DSTYK amplification may be a predictor of resistance to taxanebased treatments and represents an actionable target for these patients. (c) 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Filiaciones:
Echepare, M:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Univ Navarra, Sch Med, Dept Pathol Anat & Physiol, Pamplona, Spain
Consorcio Invest Biomed Red Canc CIBERONC, Madrid, Spain
Navarra Hlth Res Inst IDISNA, Pamplona, Spain
Picabea, B:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Univ Navarra, Sch Sci, Dept Biochem & Genet, Pamplona, Spain
Arricibita, A:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Teijeira, A:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Consorcio Invest Biomed Red Canc CIBERONC, Madrid, Spain
Navarra Hlth Res Inst IDISNA, Pamplona, Spain
Univ Navarra, CIMA, Program Immunol & Immunotherapy, Pamplona, Spain
Pasquier, A:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Zandueta, C:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Otegui, N:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Univ Navarra, Sch Med, Dept Pathol Anat & Physiol, Pamplona, Spain
Santamaría, E:
Navarra Hlth Res Inst IDISNA, Pamplona, Spain
Publ Univ Navarra UPNA, Hosp Univ Navarra HUN, Clin Neuroprote Unit, Prote Platform,Navarrabiomed, Pamplona, Spain
Fernández-Irigoyen, J:
Navarra Hlth Res Inst IDISNA, Pamplona, Spain
Publ Univ Navarra UPNA, Hosp Univ Navarra HUN, Clin Neuroprote Unit, Prote Platform,Navarrabiomed, Pamplona, Spain
:
Josep Carreras Leukaemia Res Inst IJC, Canc Genet Grp, Badalona, Spain
:
Josep Carreras Leukaemia Res Inst IJC, Canc Genet Grp, Badalona, Spain
Lecanda, F:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Hernández, J:
Hosp Univ Vall dHebron, Dept Pathol, Barcelona, Spain
Vall dHebron Inst Oncol VHIO, Barcelona, Spain
Felip, E:
Univ Autonoma Barcelona, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VIHO, Oncol Dept, Bellaterra, Spain
Cruz-Bermúdez, A:
Hosp Univ Puerta Hierro, Dept Med Oncol, Madrid, Spain
Provencio, M:
Hosp Univ Puerta Hierro, Dept Med Oncol, Madrid, Spain
Gentili, M:
Fdn IRCCS Ist Nazl Tumori, Dept Res, Tumor Genom Unit, Milan, Italy
Facchinetti, F:
Fdn IRCCS Ist Nazl Tumori, Dept Res, Tumor Genom Unit, Milan, Italy
Roz, L:
Fdn IRCCS Ist Nazl Tumori, Dept Res, Tumor Genom Unit, Milan, Italy
Montuenga, LM:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Univ Navarra, Sch Med, Dept Pathol Anat & Physiol, Pamplona, Spain
Consorcio Invest Biomed Red Canc CIBERONC, Madrid, Spain
Navarra Hlth Res Inst IDISNA, Pamplona, Spain
Valencia, K:
Univ Navarra, Program Solid Tumors, CIMA, Pio 12 Ave 55, Pamplona 31008, Spain
Consorcio Invest Biomed Red Canc CIBERONC, Madrid, Spain
Navarra Hlth Res Inst IDISNA, Pamplona, Spain
Univ Navarra, Sch Sci, Dept Biochem & Genet, Pamplona, Spain
|